Entering text into the input field will update the search result below

ImmunoGen revenues up 73%, earnings down 48%, revises guidance

Apr. 29, 2016 7:30 AM ETImmunoGen, Inc. (IMGN) StockBy: SA News Team
  • ImmunoGen (NASDAQ:IMGN) FQ3 results: Revenues: $19.7M (+72.8%); R&D Expense: $36.1M (+40.5%); SG&A: $11.2M (+60.0%); Operating Loss: ($27.6M) (-30.2%); Net Loss: ($31.9M) (-47.7%); Loss Per Share: ($0.37) (-48.0%); Quick Assets: $182.9M (-34.2%).
  • 2016 Guidance: Revenues: $60M - 70M from $70M - 80M; operating expenses: $180M - 185M from $175M - 180M; net loss: ($135M - 140M) from ($120M - 125M); cash burn: ($110M - 115M) from ($100M - 105M); capex: $13M - 15M (unch); quick assets at fiscal year end: $155M - 160M from $165M - 170M.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
IMGN--
ImmunoGen, Inc.